Immunosafety of Recombinant Human C1-Inhibitor in Hereditary Angioedema: Evaluation of IgE Antibodies

• Published in: Clinical drug investigation Vol. 33; no. 4; pp. 275 - 281
• Main Authors: Hack, C. Erik, Relan, Anurag, Baboeram, Aartie, Oortwijn, Beatrijs, Versteeg, Serge, van Ree, Ronald, Pijpstra, Rienk
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing AG 01.04.2013; Springer Nature B.V
• Subjects: Anaphylaxis - chemically induced; Angioedema; Angioedemas, Hereditary - drug therapy; Case-Control Studies; Complement C1 Inhibitor Protein - adverse effects; Complement C1 Inhibitor Protein - therapeutic use; Humans; Immunoglobulin E - biosynthesis; Internal Medicine; Medicine; Medicine & Public Health; Original Research Article; Pharmacology/Toxicology; Pharmacotherapy; Recombinant Proteins - adverse effects; Recombinant Proteins - therapeutic use; Rabbit Meat; Animal Allergen; Hereditary Angioedema; C1INH Deficiency; Anaphylactic Reaction
• ISSN: 1173-2563; 1179-1918; 1179-1918
• DOI: 10.1007/s40261-013-0064-2

Background Recombinant human C1-inhibitor (rhC1INH) purified from milk of transgenic rabbits is used for the treatment of acute attacks in patients with hereditary angioedema (HAE) due to C1-inhibitor (C1INH) deficiency. Objective The objective was to investigate the risk of rhC1INH inducing IgE ant...